

# B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

NCT05474378

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Stanford University
Enrollment	39 participants

## Plain Language Summary

---

This study is testing B7-H3 CAR-T cell therapy — immune cells engineered to attack a specific protein found on brain tumor cells — in patients with recurrent glioblastoma, the most aggressive type of brain tumor, that has come back after initial treatment.

**\*\*You may be eligible if...\*\***

- You are 18–75 years old and have been diagnosed with WHO Grade IV glioma (glioblastoma), confirmed as IDH wild-type
- Your tumor has come back after standard treatment (first recurrence) and surgery is being considered
- You have adequate blood counts, kidney, liver, and heart function
- Your overall condition allows for surgery (Karnofsky Performance Score e 60)

**\*\*You may NOT be eligible if...\*\***

- Your tumor is in its first occurrence (not yet recurrent)
- You have significant organ dysfunction (heart, liver, kidneys)
- You are on high doses of steroids (more than 4 mg decadron per day)
- You are pregnant or planning to become pregnant

Talk to your doctor to see if this trial is right for you.

## Key Eligibility Criteria

---

### Inclusion (26)

- Histologically confirmed high grade (WHO Grade IV) glioma including but not limited to glioblastoma, gliosarcoma, glioblastoma with oligodendroglial features, glioblastoma with PNET features, tested as IDH wild-type, as per revised WHO 2021 criteria. Patients must also have evidence of tumor recurrence/progression by MRI (RANO criteria) after standard front-line therapy. b. First recurrence or progressive disease after a standard line therapy.
- Resectable disease: Resection is being considered as part of the standard of care for the patient and it is thought that it is feasible that a majority of contrast-enhancing tumor mass/signal can be resected.
- Patients must be between the ages of 18 and 75 years old (inclusive).
- Karnofsky Performance score e 60.
- Use of steroids must be limited to d 4 mg of decadron daily.
- ... and 21 more (see full listing online)

### Exclusion (13)

- Pregnant or patients who are breastfeeding.
- Prior or concurrent treatment with Avastin (bevacizumab) for the purposes of recurrent disease. Avastin (bevacizumab) may have been used for radiation necrosis.
- Prior exposure to chimeric antigen receptor (CAR) based therapies.

<https://clinicaltrials.gov/study/NCT05474378> agents/reagents used in this study.

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

- Requires current anticoagulation therapy that cannot be safely paused for surgical resection and Ommaya access.
- ... and 8 more (see full listing online)

## Locations (1 total)

---

Stanford Cancer Institute, Palo Alto, California, United States